Airborne Ultrafine & Fine Particulate Matter: A Cause for Endothelial

Status Completed

Clinical Trial Summary

The purpose of this study is to examine biological pathways of altered blood vessel function resulting from breathing airborne particulate. Blood artery function in healthy men will be measured after particulate exposure either on placebo or on an asthma medication that stops production of an inflammatory biological agent. Lung and blood profiles will be obtained before and after exposure to exhaust fumes. We believe that the inflammatory agent produced by the lungs from breathing these particles causes abnormal artery function.

Clinical Trial Description

Hourly ice resurfacing by gas and propane fueled machines creates high levels of ultrafine and fine particulate matter (PM1) in indoor ice rinks. PM1 exposure may disrupt the normal nitric oxide (NO)/endothelin (ET)-1 vasodilation system and promote atherosclerosis, and/or increase the risk of an acute cardiac event. Our specific aims are 1) to determine whether impaired endothelial-mediated vasodilation and forearm muscle tissue reoxygenation rate and blood volume change (to reactive hyperemia following artery occlusion) is associated with combustion-derived PM1 exposure, and 2) To characterize a PM1 induced mechanism of endothelial dysfunction which occurs via a leukotriene (LT)-associated, airway generated tumor necrosis factor-alpha (TNF-a) mediated pathway. Healthy low PM1 exposed males will be evaluated for endothelial dysfunction before and after artery occlusion using high resolution ultrasound and near-infrared spectroscopy (NIRS), before and after moderate exercise in blinded high and low [PM1]. Endothelial dysfunction among chronically PM¬1 exposed ice rink athletes will be determined to evaluate the feasibility of using this population as a model in future studies. TNF-a, IL-8, LTB4, LTC4, LTD4, LTE4, ET-1, NO, and differential cell counts will be measured in sputum and serum. [PM1] will be monitored and exposure levels will be typical of indoor ice rinks. LT involvement will be assessed in vivo by double-blind pharmacological manipulation during PM1 exposure during light exercise. Results will demonstrate whether endothelial-mediated vasodilation and muscle hemodynamics are influenced by PM1 exposure, and will elucidate an LT initiated TNF-a mediated pathway in ET-1 upregulation. Our results should provide information for understanding the effects of PM1 exposure on the atherosclerotic process and cardiovascular risk, and give insight to novel treatment and diagnostic modalities. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00814281
Study type	Interventional
Source	Marywood University
Contact
Status	Completed
Phase	N/A
Start date	May 2007
Completion date	May 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00994175` - A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma	Phase 2
Not yet recruiting	`NCT04885738` - The Value of FeNO in Predicting Airway Eosinophilic Inflammation
Recruiting	`NCT02767973` - To Identify Persons Who Are Susceptible to WSP-induced Inflammation and Examine the Role of GSTM1 and Other Factors in This Susceptibility	N/A
Completed	`NCT03861390` - Woodsmoke Particulate + Prednisone	Phase 1/Phase 2
Completed	`NCT00869596` - Study of Biomarkers of Airway Inflammation (0000-128)	Phase 1
Completed	`NCT00455377` - Lung Function and Airway Inflammation in Portland Cement Workers	N/A
Completed	`NCT00527345` - Children's Exposures/Health Effects/Diesel Exhaust	N/A
Completed	`NCT03444298` - A Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults	Phase 2
Withdrawn	`NCT00604578` - Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat Asthma	Phase 2
Completed	`NCT00673907` - HIPWOODS - Health Effects Related to Exposure to Particle Pollution From Woodburning Stoves	N/A
Completed	`NCT00989365` - Effect of Aerobic Training on Asthmatic Patients	N/A
Completed	`NCT00635882` - Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)	Phase 2
Enrolling by invitation	`NCT03851406` - Woodsmoke Particulate + Hypertonic Saline	N/A
Completed	`NCT03924635` - An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients	Phase 4
Completed	`NCT00727714` - Lung Function and Inflammatory Markers in Cement Dust Exposed Workers: A Cross-shifts Study	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms